Randomized, Double Blind, Placebo Controlled Trial of Hydrosoluble Ubiquinol and Carnitine in Patients with Heart Failure: Longterm Follow up Results in the Tishcon Study

Abstract

Abstract:Background: Carnitine and coenzyme Q10 are important for myocardial-mitochondrial function, and are deficient in patients with congestive heart failure. It is possible that supplementation with ubiquinol + l-carnitine may be protective among these patients, which may improve the quality of life and morbidity in heart failure. Subjects and Methods:In this controlled trial, the effects of carni Q-gel (L-carnitine fumarate 2250mg/day+hydrosoluble reduced ubiquinol 270mg/day) were examined for 15 months, in 31 (intervention group A) and another 31(control group B) patients with heart failure. Hospitalization due to worsening of heart failure, heart transplantation, and deaths were the combined endpoints.

New Developments in Coenzyme Q10 Research Contributed by A Single Group. Editorial

“…Serum concentration of IL-6 and TNF-alpha, that are proinflammatory cytokines, showed a significant decline in the intervention group compared to control group which was again a novel discovery for CoQ10. Baseline serum CoQ10 (0.21±0.11 v/s 0.19+0.10ug/ml) was low, however, after 12 weeks, serum CoQ10 showed a significant increase in the carni Q-gel group compared to the control group (2.7±1.2 v/s 0.76±0.14 ug/ml) [29,30]. Serum nitrite which is is an indicator of nitric oxide showed significant increase in the CoQ10 group compared to control group.…”

“…Congestive heart failure may be associated with CoQ10 deficiency as well as with carnitine deficiency [29,30]. In a randomized, double blind controlled trial; Singh's group administered both the agents in patients with heart failure for the first time as metabolic treatment of heart failure [29,30].…”

“…Long-term follow up, after treatment for 12 months, the quality of life visual analogous scale revealed that dyspnea, palpitation and fatigue and New York Heart Association (NYHA) class II-III-IV, which were present at rest, in all the patients, at baseline, showed beneficial effects in the intervention group compared to the placebo group [30]. The deaths (3 vs. 8) and hospitalizations due to worsening of heart failure (2 vs. 11) among interven-tion and control group respectively, were significantly lower in the carni Qgel group compared to the control group (5 vs. 19, P<0.02).Treatment with carni Q-gel was stopped after 12 months.…”